XML 52 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Share based compensation (Tables)
6 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of share-based payment arrangement activity
The following table summarizes activities of the Company's RSUs for the six months ended June 30, 2024:

Number of
RSUs
Weighted
Average
Exercise Price
Weighted
Average
Fair value at
grant date
Weighted
remaining
contractual
years
Aggregate
intrinsic
value
US$US$
Outstanding at January 1, 202415,033,854 0.69 4.91 
Granted (new RSUs)117,250 — 3.51 
Exercised(4,039,195)0.03 — 
Outstanding at June 30, 202411,111,909 0.92 4.31 
Vested and expected to vest as of June 30, 202411,111,909 0.92 4.31 8.8138,054 
Exercisable as of June 30, 20249,185,844 0.92 4.26 8.9331,602 
The following table summarizes activities of the options for the six months ended June 30, 2024:

Number of
RSUs
Weighted
Average
Exercise Price
Weighted
Average
Fair value at
grant date
Weighted
remaining
contractual
years
Aggregate
intrinsic
value
US$US$
Outstanding at January 1, 202411,260,718 9.62 3.11 
Granted 4,960,570 0.50 1.21 
Forfeited(195,628)7.36 2.86 
Outstanding at June 30, 202416,025,660 6.82 2.52 
Vested and expected to vest as of June 30, 202416,025,660 6.82 2.52 8.02 
Exercisable as of June 30, 202410,884,902 8.66 2.76 7.49 
Summary of fair value of options granted that are estimated using the binomial model
The fair value of the options granted for the six months ended June 30, 2023 and 2024 are estimated using the binomial model with the following assumptions used:
Six Months Ended June 30,
20232024
Risk-free rate of return3.79 %4.69 %
Volatility44.95 %47.25 %
Expected dividend yield0.0 %0.0 %
Fair value of underlying ordinary shareUS$8.02US$1.64
Expected terms10 years10 years
Summary of compensation expense recognized for RSUs
Compensation expenses recognized for RSUs and options for the six months ended June 30, 2023 and 2024 were allocated as follows.
Six Months Ended June 30,
20232024
RMBRMB
Selling, general and administrative expenses32,565 55,066 
Research and development expenses19,661 15,859 
Total52,226 70,925